



Evogene Schedules First Quarter 2023 Financial Results Release & Conference Call for May 18, 2023

Conference call scheduled for 9AM ET

Rehovot, Israel – May 4, 2023 – Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN), a leading computational biology company aiming to revolutionize life-science product development, announced today that it will release its financial results for the first quarter of 2023, on Thursday, May 18, 2023.

Later that day, Company management will host a conference call to discuss the results at 9:00AM Eastern time, 4:00PM Israel time.

To access the conference call, please dial +1-888-281-1167 toll free from the United States, or +972-3-918-0609 internationally. Access to the call will also be available via live webcast through the Company's website at www.evogene.com.

A replay of the conference call will be available approximately two hours following the completion of the call. To access the replay, please dial +1-888-326-9310 toll free from the United States, or +972-3-925-5901 internationally. The telephone replay will be accessible for three days, but an archive of the webcast will be available from the webcast link for the following twelve months.

-XXX-

About Evogene:

Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN) is a computational biology company leveraging big data and artificial intelligence, aiming to revolutionize the development of life-science based products by utilizing cutting-edge technologies to increase the probability of success while reducing development time and cost.

Evogene established three unique tech-engines – *MicroBoost AI*, *ChemPass AI* and *GeneRator AI*. Each tech-engine is focused on the discovery and development of products based on one of the following core components: microbes (*MicroBoost AI*), small molecules (*ChemPass AI*), and genetic elements (*GeneRator AI*).



Evogene uses its tech-engines to develop products through strategic partnerships and collaborations, and its five subsidiaries including:

1. **Biomica Ltd.** (www.biomicamed.com) – developing and advancing novel microbiome-based therapeutics to treat human disorders powered by *MicroBoost AI*;
2. **Lavie Bio Ltd.** (www.lavie-bio.com) – developing and commercially advancing, microbiome based ag-biologicals powered by *MicroBoost AI*;
3. **AgPlenus Ltd.** (www.agplenus.com) – developing next generation ag-chemicals for effective and sustainable crop protection powered by *ChemPass AI*;
4. **Canonic Ltd.** (www.canonicbio.com) – developing medical cannabis products based on decoding plant genetics for optimized therapeutic effect powered by *GeneRator AI*; and
5. **Casterra Ag Ltd.** (www.casterra.co) – developing and marketing superior castor seed varieties producing high yield and high-grade oil content, on an industrial scale for the biofuel and other industries powered by *GeneRator AI*.

For more information, please visit: www.evogene.com.

Investor Contact:

Kenny Green

Email: kenny.green@evogene.com

Tel: +1 212 378 8040

Rachel Pomerantz Gerber

Email: rachel.pomerantz@evogene.com

Tel: +972 8 931 1900